LECTADE

Main information

  • Trade name:
  • LECTADE ORAL REHYDRATION THERAPY
  • Pharmaceutical form:
  • ORAL SOLUTION/SUSPENSION
  • Units in package:
  • 12x64g sachets
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • LECTADE ORAL REHYDRATION THERAPY
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CALF | CAT | DOG | HORSE FOAL | LAMB | PIGS | BEEF CALF | BITCH | BOAR | BOVINE | CALF - PODDY | CALF - PREWEANING | CALF - SUCK
  • Therapeutic area:
  • electrolyte replacer
  • Therapeutic indications:
  • DEHYDRATION | DIARRHOEA | SCOURS | ABSORPTIVE | ACUTE DIARRHOEA | ACUTE INTESTINAL CATARRH | AVIAN BLACKHEAD | BACTERIAL ENTERITIS | BLACKHEAD | CHRONIC DIARRHOEA | COCCIDIOSIS | DIETARY FACTORS | DIETARY UPSET | ENTERITIS | FEED CONVERSION | FLATULANCE | FLUID LOSS | GASTRO-INTESTINAL | GRAM NEGATIVE BACTERIA | GROWTH RATE | K88+ SEROTYPES OF E.COLI | NESTING DIARRHOEA | NON-SPECIFIC IRRITANTS | POISONING | POSTWEANING SCOURS | PROPHYLACTIC | SCOURS | SELENIUM RESPONSIVE SCOURS | STREPTOMYCIN SENSITIVE BACTERI | SULPHADIAZINE SENSITIVE BACTER | SULPHONAMIDE SENSITIVE BACTERI | TRICHOMONIASIS | TRIMETHOPRIM SENSITIVE BACTERI | WHITE SCOURS
  • Product summary:
  • A non-antibiotic supportive treatment for scouring or dehydrated calves, pigs, dogs, cats, lambs & foals. A suitable first feed for brought-in calves or stressed calves & pigs.Stressed & scouring animals requiring rehydration are at risk of multiple organ dysfunction - it is recommended that veterinary advice is sought when considering treating dehydrated animals.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 35845/61726
  • Authorization date:
  • 29-04-2014
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

LECTADE ORAL REHYDRATION THERAPY Relevant label particulars (RLPs)

31MAR14

page 1/6

(Copy in the header and footer will not appear on the final printed label)

IMMEDIATE LABEL (SACHET) - FRONT PANEL

FOR ANIMAL TREATMENT ONLY

SECTION

LECTADE

®

ORAL REHYDRATION THERAPY

ACTIVE CONSTITUENTS Section A

Glycine

6.18 g

Citric Acid Monohydrate

0.48 g

Potassium Phosphate Monobasic 4.08 g

Potassium Citrate

0.12 g

Sodium Chloride

8.58 g

SECTION

ALONG

THIS

LINE

ACTIVE CONSTITUENTS Section B

Glucose

44.61 g

A non-antibiotic supportive treatment for scouring or dehydrated calves, pigs, dogs, cats, lambs

and foals. A suitable first feed for bought-in calves or stressed calves and pigs.

IMPORTANT: Each sachet is divided into two sections.

The contents of section A and section B must always be used together.

64 g

DIRECTIONS FOR PREPARATION: See over.

STORE below 25

C (Air Conditioning) in a dry place.

EXP.

[Item code]

APVMA Approval No. 35845/61726

[Jurox logo]

RLP

APPROVED

LECTADE ORAL REHYDRATION THERAPY Relevant label particulars (RLPs)

31MAR14

page 2/6

(Copy in the header and footer will not appear on the final printed label)

IMMEDIATE LABEL (SACHET) - BACK PANEL

SECTION

READ CARTON BEFORE USING THIS PRODUCT

DIRECTIONS FOR USE

To prepare Lectade

solution, add the contents of Section A and Section B to 2 litres of warm

water. Stir until dissolved. Feed the quantity of Lectade

, as prescribed, and refrigerate the

remainder until the next treatment is required. Prepare fresh Lectade

solution daily. Sections

A and B must be used together. If quantities less than 2 litres are required, 500 mL of Lectade

solution can be prepared using a 5 mL medicine spoon. In this case, add 1 level spoonful of

powder from section A to 3 heaped spoonfuls of powder from section B. Stir until dissolved.

WITHHOLDING PERIOD: Zero (0) days.

TRADE ADVICE

EXPORT SLAUGHTER INTERVAL (ESI): Zero (0) days.

DISPOSAL: Dispose of empty sachet by wrapping with paper and putting in garbage.

SECTION

PRESCRIBING INFORMATION

Animal’s Name:……………………………………………

Owner’s Name:…………………………………………….

Dosage Instructions:………………………………………

……………………………………………………………….

……………………………………………………………….

……………………………………………………………….

Jurox Pty Limited

85 Gardiner Street

Rutherford NSW 2320

LECTADE ORAL REHYDRATION THERAPY Relevant label particulars (RLPs)

31MAR14

page 3/6

(Copy in the header and footer will not appear on the final printed label)

PRIMARY LABEL (CARTON) - FRONT PANEL

FOR ANIMAL TREATMENT ONLY

LECTADE

®

ORAL REHYDRATION THERAPY

Each duo-sachet contains:

Glycine

6.18 g

Citric Acid Monohydrate

0.48 g

Potassium Phosphate Monobasic 4.08 g

Potassium Citrate

0.12 g

Sodium Chloride

8.58 g

Glucose

44.61 g

An oral, non-antibiotic supportive treatment for scouring or dehydrated dogs, cats, calves, pigs,

lambs and foals.

12 x 64 g sachets NET

PRIMARY LABEL (CARTON) - LEFT SIDE

A non-antibiotic supportive treatment for scours and dehydration, whether due to nutritional,

bacterial or viral causes.

Stressed and scouring animals requiring rehydration are at risk of multiple organ

dysfunction. It is strongly recommended that veterinary advice is sought when

considering treating dehydrated animals.

DIRECTIONS FOR USE IN CALVES PIGS AND LAMBS

Dogs, Cats and Foals: Refer to the opposite end of this carton.

Add the contents of Section A and Section B of one Lectade

sachet to 2 litres of warm water.

Stir until dissolved. Feed the appropriate quantity of Lectade

and store remainder in a cool

place until next treatment is required. Prepare fresh Lectade

solution daily.

Section A and B must always be used together when preparing Lectade

®

solution.

500 ml of Lectade

solution can be made up using a 5 mL medicine spoon, by adding 1 level

spoonful of powder from section A and 3 heaped spoonfuls of powder from Section B to 500 mL

of warm water. Stir until dissolved.

General Note: Where specific disease control (e.g. antibiotic therapy) is indicated, this can be

administered in conjunction with Lectade

LECTADE ORAL REHYDRATION THERAPY Relevant label particulars (RLPs)

31MAR14

page 4/6

(Copy in the header and footer will not appear on the final printed label)

PRIMARY LABEL (CARTON) - LEFT SIDE (continued)

CALVES

Scouring Calves

Dose rate: 1 to 1.5 L / 10 kg bodyweight daily, divided into two or more daily doses. If the

scouring is established or severe causing serious dehydration, the higher dose should be used

initially and fed in 3 or 4 divided doses. 2 litres of solution given night and morning will be

adequate in many cases.

To maintain adequate energy and nutrient intake, milk feeding should continue as normal

during periods of scouring. Diluted Lectade

solution should be given between these milk feeds.

Replace with fresh solution every 24 hours. Fresh drinking water should be available at all

times.

Keep feeding utensils clean and avoid overfeeding.

Normal feeding should be resumed after the course of treatment. Many scouring problems can

be avoided by feeding adequate colostrum early in the calf’s life. Seek veterinary advice if blood

is present or if scours persist beyond 4 days.

Bought-in or Stressed Calves

Feed 2 litres of solution made up as directed, instead of milk as the first feed on arrival. For the

next scheduled feed, use 1 litre of solution together with 1 litre of milk or milk replacer.

Thereafter feed normal diet. Adequate colostrum should be fed to calves.

PIGS

Suckling pigs

Immediately scour symptoms show, fresh solution made up as directed should be made

available, in a cube drinker, or similar clean vessel, to the whole litter. As a guide, a litter of 1

week old piglets will consume 2-3 litres per day.

Weaned pigs

Weaned pigs, showing signs of scour, should have fresh solution made available in a suitable

clean vessel, cube drinker, trough or drum with nipple drinker (depending on the size of the

group). As a guide each weaner will consume approximately 1 – 2 litres per day.

Duration of treatment (All pigs):

Lectade

should be made available for 4 days. If there has been some improvement after 4

days, but the scour has not cleared completely, treatment may be continued for up to 8 days in

total.

LAMBS

Lectade

solution made up as directed should be administered orally to scouring or dehydrated

neonatal lambs by drenching bottle or stomach tube. As a guide, 150 mL of Lectade

solution 3

times daily is a suitable dosage regimen.

LECTADE ORAL REHYDRATION THERAPY Relevant label particulars (RLPs)

31MAR14

page 5/6

(Copy in the header and footer will not appear on the final printed label)

PRIMARY LABEL (CARTON) - LEFT SIDE (continued)

WITHHOLDING PERIOD: Zero (0) days.

TRADE ADVICE

EXPORT SLAUGHTER INTERVAL (ESI): Zero (0) days.

PRIMARY LABEL (CARTON) - RIGHT SIDE

A non-antibiotic supportive treatment for scours and dehydration including that resulting from

debilitating viral disease such as canine parvovirus and feline panleucopaenia.

DIRECTIONS FOR USE IN DOGS, CATS AND FOALS

Calves, lambs and pigs: Refer to the opposite end of this carton.

Add the contents of Section A and Section B of one Lectade

sachet to 2 litres of warm water.

Stir until dissolved. Feed the appropriate quantity of Lectade

and store remainder in a cool

place until the next treatment is required. Prepare fresh Lectade

solution daily.

Section A and B must always be used together when preparing Lectade

®

solution.

500 mL of Lectade

solution can be made up using a 5 mL medicine spoon, by adding 1 level

spoonful of powder from section A and 3 heaped spoonfuls of powder from section B to 500 mL

of warm water. Stir until dissolved.

General note: Where specific disease control (e.g. antibiotic therapy) is indicated, this can be

administered in conjunction with Lectade

DOGS AND CATS

Lectade

solution, reconstituted as directed, should be made available to diarrhoeic or

dehydrated animals as supportive therapy following specific treatment for the conditions

described. As a guide, the following dosage regimens are recommended:

Cats and Miniature dogs (Up to 5 kg)

125 mL 2-3 times daily

Small dogs (5 – 10 kg)

250 mL 2-3 times daily

Medium dogs (11 – 20 kg)

500 mL 2-3 times daily

Large dogs (Over 20 kg)

750 mL 2-3 times daily

Many dogs find Lectade

palatable and will drink the solution voluntarily. Palatability for cats is

variable. Lectade

may also be administered orally via dosing-syringe.

Treatment should be continued for 1-2 days after the animal appears clinically recovered and is

feeding normally.

FOALS

Lectade

solution, made up as directed has been administered orally to scouring or dehydrated

foals by drenching bottle or stomach tube. As a guide, 1-2 litres of Lectade

2-3 times daily,

depending on bodyweight and severity, has been reported as a suitable dosage regimen for

neonatal foals.

LECTADE ORAL REHYDRATION THERAPY Relevant label particulars (RLPs)

31MAR14

page 6/6

(Copy in the header and footer will not appear on the final printed label)

PRIMARY LABEL (CARTON) - BACK PANEL

FOR ANIMAL TREATMENT ONLY

LECTADE

®

ORAL REHYDRATION THERAPY

REPLACES LOST FLUIDS AND ELECTROLYTES

FIRST AID: If poisoning occurs, contact a doctor or Poisons Information Centre. Phone

Australia 13 1126.

STORE below 25

C (Air Conditioning) in a dry place.

DISPOSAL: Wrap with paper and put in garbage.

B.

EXP.

Jurox Pty Limited

85 Gardiner Street

Rutherford NSW 2320

[Jurox logo]

[Item code]

APVMA Approval No. 35845/61726

PRIMARY LABEL (CARTON) - LID

LECTADE

®

ORAL REHYDRATION THERAPY

REPLACES LOST FLUIDS AND ELECTROLYTES

[Jurox logo]

28-11-2018

Sprout Creek Farm Recalls “Kinkead” Cheese due to Possible Health Risk

Sprout Creek Farm Recalls “Kinkead” Cheese due to Possible Health Risk

Sprout Creek Farm of Poughkeepsie, New York is recalling 4 wheels of “Kinkead” cheese made on 5-10-18, because it has the potential to be contaminated with Listeria monocytogenes. Listeria monocytogenes is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, L...

FDA - U.S. Food and Drug Administration

27-11-2018

Risk assessment of new sequencing information for genetically modified soybean A2704‐12

Risk assessment of new sequencing information for genetically modified soybean A2704‐12

Published on: Mon, 26 Nov 2018 The GMO Panel has previously assessed genetically modified (GM) soybean A2704‐12. This soybean was found to be as safe and nutritious as its conventional counterpart with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 5 June 2018, the European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soybean A2704‐12 and to indicate whether the previous c...

Europe - EFSA - European Food Safety Authority Publications

10-1-2019


Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment

Orphan designation: glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine, Treatment of maple syrup urine disease, 26/10/2018, Positive

Europe - EMA - European Medicines Agency

26-11-2018


Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Withdrawn application: HopGuard Gold, purified semi-solid extract from Humulus lupulus L. containing approximately 48% of beta acids as potassium salts, Date of withdrawal: 12/04/2018, Initial authorisation

Europe - EMA - European Medicines Agency

22-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type: , therapeutic area: , PIP number: P/0223/2018

Europe - EMA - European Medicines Agency

21-11-2018

EU/3/18/2081 (Pharma Gateway AB)

EU/3/18/2081 (Pharma Gateway AB)

EU/3/18/2081 (Active substance: 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid) - Orphan designation - Commission Decision (2018)7790 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/096/18

Europe -DG Health and Food Safety

5-11-2018

EU/3/18/2070 (Accelsiors CRO and Consultancy Services Ltd)

EU/3/18/2070 (Accelsiors CRO and Consultancy Services Ltd)

EU/3/18/2070 (Active substance: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid) - Orphan designation - Commission Decision (2018)7271 of Mon, 05 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/114/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Active substance: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine) - Orphan designation - Commission Decision (2018)7277 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/18

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2056 (Nogra Pharma Limited)

EU/3/18/2056 (Nogra Pharma Limited)

EU/3/18/2056 (Active substance: (S)-(-)-3-(4-aminophenyl)-2-methoxypropanoic acid) - Orphan designation - Commission Decision (2018)5728 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/075/18

Europe -DG Health and Food Safety

18-5-2018

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Active substance: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid) - Transfer of orphan designation - Commission Decision (2018)3149 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/14/T/01

Europe -DG Health and Food Safety

18-5-2018

EU/3/13/1220 (IQVIA RDS Ireland Limited)

EU/3/13/1220 (IQVIA RDS Ireland Limited)

EU/3/13/1220 (Active substance: Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}ethyl]sulfanyl}-3-{[(2S)-1-ethoxy-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}propanamido)-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)propanoyl Ethyl ester) )-methoxy]acetyl}oxy)butyl)sulfanyl]-3-(hexadecylcarbamoyl)propanoic acid]-poly(ethylene glycol)-este...

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Active substance: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene) - Orphan designation - Commission Decision (2018)2403 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/255/17

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/1991 (TurnKey PharmaConsulting Ireland Limited)

EU/3/18/1991 (TurnKey PharmaConsulting Ireland Limited)

EU/3/18/1991 (Active substance: Docosahexaenoic acid ethyl ester) - Orphan designation - Commission Decision (2018)1880 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/235/17

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/2000 (Amicus Therapeutics UK Ltd)

EU/3/18/2000 (Amicus Therapeutics UK Ltd)

EU/3/18/2000 (Active substance: Recombinant human acid alpha-glucosidase) - Orphan designation - Commission Decision (2018)1877 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/230/17

Europe -DG Health and Food Safety